MAJOR INCIDENT
462 Administrative and Legal Issues
(c) symptoms include watering eyes, blepharospasm, skin
erythema, dyspnoea, cough and wheeze, with pneumonitis
and non-cardiogenic pulmonary oedema
(d) death may follow high concentrations with mass
displacement of air/oxygen
(e) treatment includes decontamination and supportive care
with inhaled bronchodilators and steroids, and if required,
mechanical ventilation until resolution of the acute lung injury.
Biological incident
Biological incidents take two distinct forms: natural phenomena such as an inf lu-
enza pandemic or dengue epidemic, and deliberate release or a ‘white powder’- type
incident.
1 Naturally occurring incidents are managed in accordance with current
infectious disease isolation and treatment procedures.
2 A range of biological pathogens could potentially be used in a deliberate
release incident. These include:
(i) Bacteria such as the plague, viruses such as smallpox, spores such
as anthrax, fungi such as Fusarium or toxins such as ricin
(a) some have also been genetically engineered to produce
resistance to usual recognized treatments.
3 As effects from contamination with a biological agent may take days or even
weeks to manifest, a major challenge in any deliberate release incident is to
recognize it and to initiate the appropriate systems response.
(i) ED staff must be alert to an unusual pattern of infectious disease
and should liaise closely with infectious disease and population
health specialists.
(ii) Patterns that may indicate possible deliberate release include:
(a) unusual illness, e.g. sudden unexplained febrile death, critical
illness or pneumonia death in a previously healthy young
adult
(b) unexpected number of patients with the same symptoms
(c) unusual illness for that time of year, e.g. influenza in summer
(d) unusual illness for the patient’s age group, e.g. chickenpox in
a middle-aged adult
(e) illness in an uncommon patient category, e.g. cutaneous
anthrax in a patient with no history of contact with animals,
animal hides or products
(f) illness acquired in a non-endemic area
(g) unusual clinical signs, e.g. mediastinal widening on chest
radiograph (CXR), sudden onset of symmetrical flaccid
paralysis
(h) atypical progression of an illness, e.g. lack of response to
usually effective antibiotics.